Islet Sciences gets rights to remogliflozin from BHV
Executive Summary
BHV Pharma Inc. (Brighthaven Ventures) licensed Islet Sciences Inc. exclusive worldwide rights--excluding Japan, Korea, Taiwan, China, and Latin America--to develop and commercialize its Phase IIb SGLT2 inhibitor remogliflozin etabonate for Type II diabetes and nonalcoholic steatohepatitis (NASH).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice